TSPO-PET for Neuroinflammation in Parkinson's Disease
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this substudy is to measure the concentration and the regional brain
distribution of activated brain microglia/macrophages using the PET (Positron Emission
Tomography) ligand [18F]DPA-714 in participants enrolled in the UAB Neuroinflammation in PD
study. The PET tracer [18F]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known
as the peripheral benzodiazepine receptor) in the mitochondria of activated
microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount
and distribution of [18F]DPA-714 in the brain will be correlated to clinical data acquired
through the separate ongoing Neuroinflammation in PD study. The primary objective of this
study is to determine if patients with PD have higher levels of neuroinflammation than
healthy controls as measured with [18F]DPA-714-PET/MRI.